Top

The International Journal of Cardiovascular Imaging

Published in:

Open Access 01-01-2013 | Original Paper

Infarct tissue characterization in implantable cardioverter-defibrillator recipients for primary versus secondary prevention following myocardial infarction: a study with contrast-enhancement cardiovascular magnetic resonance imaging

Published in: The International Journal of Cardiovascular Imaging | Issue 1/2013

Abstract

Knowledge about potential differences in infarct tissue characteristics between patients with prior life-threatening ventricular arrhythmia versus patients receiving prophylactic implantable cardioverter-defibrillator (ICD) might help to improve the current risk stratification in myocardial infarction (MI) patients who are considered for ICD implantation. In a consecutive series of (ICD) recipients for primary and secondary prevention following MI, we used contrast-enhanced (CE) cardiovascular magnetic resonance (CMR) imaging to evaluate differences in infarct tissue characteristics. Cine-CMR measurements included left ventricular end-diastolic and end-systolic volumes (EDV, ESV), left ventricular ejection fraction (LVEF), wall motion score index (WMSI), and mass. CE-CMR images were analyzed for core, peri, and total infarct size, infarct localization (according to coronary artery territory), and transmural extent. In this study, 95 ICD recipients were included. In the primary prevention group (n = 66), LVEF was lower (23 ± 9 % vs. 31 ± 14 %; P < 0.01), ESV and WMSI were higher (223 ± 75 ml vs. 184 ± 97 ml, P = 0.04, and 1.89 ± 0.52 vs. 1.47 ± 0.68; P < 0.01), and anterior infarct localization was more frequent (P = 0.02) than in the secondary prevention group (n = 29). There were no differences in infarct tissue characteristics between patients treated for primary versus secondary prevention (P > 0.6 for all). During 21 ± 9 months of follow-up, 3 (5 %) patients in the primary prevention group and 9 (31 %) in the secondary prevention group experienced appropriate ICD therapy for treatment of ventricular arrhythmia (P < 0.01). There was no difference in infarct tissue characteristics between recipients of ICD for primary versus secondary prevention, while the secondary prevention group showed a higher frequency of applied ICD therapy for ventricular arrhythmia.

Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M et al (2006) ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114(10):e385–e484PubMedCrossRef

A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N Engl J Med 1997 337(22):1576–1583

Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R et al (2005) Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352(3):225–237PubMedCrossRef

Kuck KH, Cappato R, Siebels J, Ruppel R (2000) Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest : the Cardiac Arrest Study Hamburg (CASH). Circulation 102(7):748–754PubMedCrossRef

Strauss DG, Selvester RH, Lima JA, Arheden H, Miller JM, Gerstenblith G et al (2008) ECG quantification of myocardial scar in cardiomyopathy patients with or without conduction defects: correlation with cardiac magnetic resonance and arrhythmogenesis. Circ Arrhythm Electrophysiol 1(5):327–336PubMedCrossRef

Kraaier K, Verhorst PM, van Dessel PF, Wilde AA, Scholten MF (2009) Towards a better risk stratification for sudden cardiac death in patients with structural heart disease. Neth Heart J 17(3):101–106PubMedCrossRef

Kraaier K, van Dessel PF, van der Palen J, Wilde AA, Scholten MF (2009) ECG quantification of myocardial scar does not differ between primary and secondary prevention ICD recipients with ischemic heart disease. Pacing Clin Electrophysiol 33(2):192–197PubMedCrossRef

Roes SD, Borleffs CJ, van der Geest RJ, Westenberg JJ, Marsan NA, Kaandorp TA et al (2009) Infarct tissue heterogeneity assessed with contrast-enhanced MRI predicts spontaneous ventricular arrhythmia in patients with ischemic cardiomyopathy and implantable cardioverter-defibrillator. Circ Cardiovasc Imaging 2(3):183–190PubMedCrossRef

Schmidt A, Azevedo CF, Cheng A, Gupta SN, Bluemke DA, Foo TK et al (2007) Infarct tissue heterogeneity by magnetic resonance imaging identifies enhanced cardiac arrhythmia susceptibility in patients with left ventricular dysfunction. Circulation 115(15):2006–2014PubMedCrossRef

10.

Bolick DR, Hackel DB, Reimer KA, Ideker RE (1986) Quantitative analysis of myocardial infarct structure in patients with ventricular tachycardia. Circulation 74(6):1266–1279PubMedCrossRef

11.

Cardinal R, Vermeulen M, Shenasa M, Roberge F, Page P, Helie F et al (1988) Anisotropic conduction and functional dissociation of ischemic tissue during reentrant ventricular tachycardia in canine myocardial infarction. Circulation 77(5):1162–1176PubMedCrossRef

12.

Karagueuzian HS, Fenoglio JJ Jr, Weiss MB, Wit AL (1979) Protracted ventricular tachcardia induced by premature stimulation of the canine heart after coronary artery occlusion and reperfusion. Circ Res 44(6):833–846PubMedCrossRef

13.

Saeed M, Bremerich J, Wendland MF, Wyttenbach R, Weinmann HJ, Higgins CB (1999) Reperfused myocardial infarction as seen with use of necrosis-specific versus standard extracellular MR contrast media in rats. Radiology 213(1):247–257PubMed

14.

Pascale P, Schlaepfer J, Oddo M, Schaller MD, Vogt P, Fromer M (2009) Ventricular arrhythmia in coronary artery disease: limits of a risk stratification strategy based on the ejection fraction alone and impact of infarct localization. Europace 11(12):1639–1646PubMedCrossRef

15.

Raitt MH, Klein RC, Wyse DG, Wilkoff BL, Beckman K, Epstein AE et al (2003) Comparison of arrhythmia recurrence in patients presenting with ventricular fibrillation versus ventricular tachycardia in the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial. Am J Cardiol 91(7):812–816PubMedCrossRef

16.

Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS et al (2002) Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346(12):877–883PubMedCrossRef

17.

Moss AJ, Greenberg H, Case RB, Zareba W, Hall WJ, Brown MW et al (2004) Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. Circulation 110(25):3760–3765PubMedCrossRef

18.

van Welsenes GH, van Rees JB, Borleffs CJ, Cannegieter SC, Bax JJ, van Erven L et al (2011) Long-term follow-up of primary and secondary prevention implantable cardioverter defibrillator patients. Europace 13(3):389–394PubMedCrossRef

19.

Thygesen K, Alpert JS, White HD, On behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction (2007) Universal definition of myocardial infarction. Eur Heart J 28:2525–2538

20.

Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK et al (2002) Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 105(4):539–542PubMedCrossRef

21.

Amado LC, Gerber BL, Gupta SN, Rettmann DW, Szarf G, Schock R et al (2004) Accurate and objective infarct sizing by contrast-enhanced magnetic resonance imaging in a canine myocardial infarction model. J Am Coll Cardiol 44(12):2383–2389PubMedCrossRef

22.

Roes SD, Kelle S, Kaandorp TA, Kokocinski T, Poldermans D, Lamb HJ et al (2007) Comparison of myocardial infarct size assessed with contrast-enhanced magnetic resonance imaging and left ventricular function and volumes to predict mortality in patients with healed myocardial infarction. Am J Cardiol 100(6):930–936PubMedCrossRef

23.

Tarantini G, Razzolini R, Cacciavillani L, Bilato C, Sarais C, Corbetti F et al (2006) Influence of transmurality, infarct size, and severe microvascular obstruction on left ventricular remodeling and function after primary coronary angioplasty. Am J Cardiol 98(8):1033–1040PubMedCrossRef

24.

Yokota H, Heidary S, Katikireddy CK, Nguyen P, Pauly JM, McConnell MV et al (2008) Quantitative characterization of myocardial infarction by cardiovascular magnetic resonance predicts future cardiovascular events in patients with ischemic cardiomyopathy. J Cardiovasc Magn Reson 10(1):17PubMedCrossRef

25.

Bello D, Fieno DS, Kim RJ, Pereles FS, Passman R, Song G et al (2005) Infarct morphology identifies patients with substrate for sustained ventricular tachycardia. J Am Coll Cardiol 45(7):1104–1108PubMedCrossRef

26.

de Bakker JM, van Capelle FJ, Janse MJ, Wilde AA, Coronel R, Becker AE et al (1988) Reentry as a cause of ventricular tachycardia in patients with chronic ischemic heart disease: electrophysiologic and anatomic correlation. Circulation 77(3):589–606PubMedCrossRef

27.

Bezzina CR, Pazoki R, Bardai A, Marsman RF, de Jong JS, Blom MT et al (2010) Genome-wide association study identifies a susceptibility locus at 21q21 for ventricular fibrillation in acute myocardial infarction. Nat Genet 42(8):688–691PubMedCrossRef

28.

Wu Y, Chan CW, Nicholls JM, Liao S, Tse HF, Wu EX (2009) MR study of the effect of infarct size and location on left ventricular functional and microstructural alterations in porcine models. J Magn Reson Imaging 29(2):305–312PubMedCrossRef

29.

Zeppenfeld K, van der Geest RJ (2011) The infarct characteristics on magnetic resonance imaging and ventricular tachycardia: do we see what we need to see? Europace 13(6):770–772PubMedCrossRef

30.

Schelbert EB, Hsu LY, Anderson SA, Mohanty BD, Karim SM, Kellman P et al (2010) Late gadolinium-enhancement cardiac magnetic resonance identifies postinfarction myocardial fibrosis and the border zone at the near cellular level in ex vivo rat heart. Circ Cardiovasc Imaging 3(6):743–752PubMedCrossRef

31.

Bondarenko O, Beek AM, Hofman MB, Kuhl HP, Twisk JW, van Dockum WG et al (2005) Standardizing the definition of hyperenhancement in the quantitative assessment of infarct size and myocardial viability using delayed contrast-enhanced CMR. J Cardiovasc Magn Reson 7(2):481–485PubMedCrossRef

32.

Wong DT, Leung MC, Richardson JD, Puri R, Bertaso AG, Williams K et al (2012) Cardiac magnetic resonance derived late microvascular obstruction assessment post ST-segment elevation myocardial infarction is the best predictor of left ventricular function: a comparison of angiographic and cardiac magnetic resonance derived measurements. Int J Cardiovasc Imaging. doi: 10.1007/s10554-012-0021-9

Title: Infarct tissue characterization in implantable cardioverter-defibrillator recipients for primary versus secondary prevention following myocardial infarction: a study with contrast-enhancement cardiovascular magnetic resonance imaging
Publication date: 01-01-2013
Published in: The International Journal of Cardiovascular Imaging / Issue 1/2013
Print ISSN: 1569-5794
Electronic ISSN: 1875-8312
DOI: https://doi.org/10.1007/s10554-012-0077-6

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Infarct tissue characterization in implantable cardioverter-defibrillator recipients for primary versus secondary prevention following myocardial infarction: a study with contrast-enhancement cardiovascular magnetic resonance imaging

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2013

Effect of protocol choice on phase contrast cardiac magnetic resonance flow measurement in the ascending aorta: breath-hold and non-breath-hold

Is there a role for thoracic aortic calcium to fine-tune cardiovascular risk prediction?

Prevalence of thoracic aortic calcification and its relationship to cardiovascular risk factors and coronary calcification in an unselected population-based cohort: the Heinz Nixdorf Recall Study

Acknowledgments

Cardiac computed tomographic imaging to evaluate myocardial scarring/fibrosis in patients with hypertrophic cardiomyopathy: a comparison with cardiac magnetic resonance imaging

Contrast media volume optimization in high-pitch dual-source CT coronary angiography: feasibility study

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page